ClinicalTrials.gg
WithdrawnNCT04072367FIRSTUpdated Apr 27, 2023

FIrst-Pass Reperfusion With the NeVa Stent-Retriever Trial

An interventional study of NeVa Stent Retrievers and Solitaire Stent Retrievers in Acute Ischemic Stroke, sponsored by Vesalio. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by Vesalio · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
The study was withdrawn due to a change in company strategy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to compare the safety, performance and efficacy of blood clot (thrombus) removal in subjects presenting with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.

Read the detailed description

A pivotal, randomized, open label, assessor-blinded, 90-day study designed to compare the safety, performance and efficacy of thrombus removal in subjects aged ≥ 18 years presenting with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.

A total of 414 eligible subjects will be randomized in a 1:1 ratio to one of two treatment groups:

  • Active Treatment Group
  • Control Device
02

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

03

In context

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Lead sponsor

Vesalio is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • A new focal disabling neurologic deficit consistent with acute cerebral ischemia
  • NIHSS score ≥ 6;
  • Prestroke mRS score of ≤ 2;
  • Angiographic confirmation by DSA of an occlusion (eTICI 0-1) of the intracranial ICA, MCA-M1, MCA-M2, basilar artery, or intracranial vertebral artery with or without tandem involvement of the cervical ICA or cervical vertebral artery;
  • Imaging Criteria:

    1. Strokes in the Anterior Circulation:

      • Non-Contrast CT (NCCT): ASPECTS 6 to 10 on baseline CT, or
      • CT perfusion (with Automated Volume Calculation): core infarct volume ≤ 70cc and Mismatch Ratio ≥ 1.5
      • CT perfusion (without Automated Volume Calculation): ASPECTS 6 to 10 on the CBV maps with Visualized MTT or TMax - CBV Mismatch greater than 50%, or
      • Brain MRI: ASPECTS 6 to 10 (and \<70cc if Automated Volume Calculation is available) on baseline diffusion-weighted sequence (DWI).
    2. Strokes in the Posterior Circulation: pc-ASPECTS score 8 to 10 on baseline NCCT, CTA-source images, or DWI MRI.

      • Subjects for whom IV-tPA is indicated and who are available for treatment, are treated with IV-tPA within 4.5 hours of stroke onset (onset time is defined as the last time when the subject was witnessed to be at baseline), with verification that the subject has received/is receiving the correct IV t-PA dose for the estimated weight
      • Arterial puncture within 12 hours of symptom onset (or time last seen well - TLSW), thrombectomy procedure able to be completed within 2 hours from procedure start (arterial puncture).
      • Subject or legal representative is able and willing to give .

Exclusion criteria

Exclusion Criteria:

  • Rapid neurological improvement prior to groin puncture suggestive of resolution of stroke
  • Seizures at stroke onset if it makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.

    • Note: Subjects with a questionable seizure at onset of stroke should not be excluded if DSA confirms the presence of intracranial ICA and/or M1 occlusion, and accurate NIHSS can be obtained.
  • Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
  • Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre-treatment pulmonary aspiration.
  • Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
  • Cerebral vasculitis.
  • History of severe allergy to contrast medium.
  • Known allergy to stent retriever materials (nitinol, stainless steel);
  • Suspicion of aortic dissection, septic embolus, or bacterial endocarditis.
  • Active infection.
  • Baseline CT or MRI showing mass effect or intracranial tumor (except small meningioma [≤ 3 cm]).
  • CT or MRI evidence of recent/fresh hemorrhage on presentation.
  • CTA, MRA, or DSA evidence of flow limiting carotid dissection, high-grade stenosis, or complete cervical carotid occlusion requiring stenting at the time of the index procedure (i.e., mechanical thrombectomy).
  • Evidence of dissection in the intracranial cerebral arteries;
  • Uncontrolled hypertension on presentation (defined as SBP > 220 mmHg and / or DBP > 120 mmHg). For subjects placed on intravenous BP medication, uncontrolled hypertension is defined as SBP > 185 mmHg and / or DBP > 110 mmHg.
  • Baseline of \< 7 mmol/L.
  • Baseline count \< 50,000/uL.
  • Renal failure as defined by a serum creatinine >3.0 mg/dL (264 mmol/L).

    • Note: subjects on renal dialysis may be treated regardless of serum creatinine levels.
  • Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with > 3.0 or PTT > 3 times normal. Subjects on factor Xa inhibitor for 24-48 h ago must have a normal PTT.
  • Baseline blood glucose of \< 50 mg/dL (2.78 mmol) or > 400 mg/dL (22.20 mmol). Note: The ''correction'' of baseline glucose or coagulation laboratory values to meet inclusion criteria will not be allowed.
  • Females who are pregnant or breastfeeding.
  • Known current or recent use of illicit drugs or alcohol abuse.
  • Use of an drug or device within past 3 months;
  • less than 6 months.
  • Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Active Treatment Group

    NeVa Stent Retrievers

    Device: NeVa Stent Retrievers

  • Other
    Control Device

    Solitare Stent Retrievers

    Device: Solitaire Stent Retrievers

Interventions

  • DeviceNeVa Stent Retrievers

    thrombus removal

  • DeviceSolitaire Stent Retrievers

    thrombus removal

06

What researchers measure

Primary outcomes

  1. Reperfusion rate

    The primary study endpoint is the reperfusion rate of the occluded target vessel (defined by an eTICI score ≥ 2b) following one single pass using the assigned stent retriever device(s)

    Time frame: post-procedure day 0

Secondary outcomes

  1. Stent retriever comparison

    The secondary endpoint is the proportion of subjects treated with the NeVa device with good clinical outcomes at the Day 90 evaluation (defined as mRS score ≤ 2) when compared to the subjects treated with the predicate.

    Time frame: Day 90

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2020; primary completion for Dec 2020, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2019
First posted
Aug 28, 2019
StartEst.
Dec 2020
Primary completionEst.
Dec 2020
CompletionEst.
Dec 2020
Last update
Apr 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04072367
Lead sponsor
Vesalio
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Dec 2020 (estimated)
Primary completion
Dec 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Apr 27, 2023

Study contacts

Raul Gomes Nogueira, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion